Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer
Yoshimasa Shiraishi(Kyushu University), Isamu Okamoto(Kyushu University Hospital), Motoko Tachihara(Kobe University), Morihito Okada(Hiroshima University), Noriko Yanagitani(The Cancer Institute Hospital), Takehito Shukuya(Juntendo University), Nobuyuki Yamamoto(Wakayama Medical University), Kazumi Nishino(Osaka Medical Center for Cancer and Cardiovascular Diseases), Kazushige Wakuda(Shizuoka Cancer Center), Satoru Miura(Niigata Cancer Center Hospital), Koichi Takayama(Kyoto Prefectural University of Medicine), Haruhiro Saito(Kanagawa Cancer Center), Osamu Hataji(Soka Municipal Hospital), Hidetoshi Hayashi(Kindai University), Koichi Azuma(Kyushu University Hospital), Hirotaka Matsumoto(Hyogo Prefectural Amagasaki General Medical Center), Yuki Sato(Goethe University Frankfurt), Toshiyuki Kozuki(Shikoku Cancer Center), Tomohiro Sakamoto(Memorial Sloan Kettering Cancer Center), Hideaki Mizutani(Nippon Medical School), Haruko Daga(Osaka City General Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Taishi Harada(Fukuyama City Hospital), Akito Hata, Masahide Mori(Toneyama National Hospital), Asuka Tsuya(Izumi City General Hospital), Junji Kishimoto(Kyushu University Hospital)
Cited by 52
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k